“We expect to submit Tavapadon for regulatory review later this year with commercialization expected in 2026.”

In context

“g continued strong uptake in Japan and Europe. We are also pleased with the early launch feedback in the US, where revenues are expected to ramp gradually over the next couple of quarters as we work to establish the appropriate Medicare coverage and benefit determination. Lastly, we are making excellent progress with the development of Tavapadon in Parkinson's disease. This first in class D1D5 selective dopamine agonist has a favorable benefit risk profile and the potential to differentiate in several areas, such as sedation and impulse control. Tavapadon could potentially be used as a monotherapy for early Parkinson's disease as well as an adjunctive therapy to levodopa for more advanced patients, which would be a complementary addition to our existing PD portfolio with VYALEV and DUOPA. We expect to submit Tavapadon for regulatory review later this year with commercialization expected in 2026. Overall, I'm extremely pleased with the execution and strong momentum across our commercial portfolio. And with that, I'll turn the call over to Roopal for comments on our R&D highlights. Roopal Thakkar: Thank you, Jeff. I will start with immunology. We received European approval for Rinvoq in GCA and expect FDA approval soon. We remain on track for several important data readouts this year as well including Phase III data for Rinvoq in alopecia areata and vitiligo and data from Skyrizi's head to head study in psoriasis versus SOTIQ2 [ph]. Our early and mid-stage immunology pipeline continues to advance. Recent initiations include a Phase II study evaluating Skyrizi in combination with Lutikizumab in psoriatic arthritis and a Phase I study for our next generation TL1A antibody, which is d”